期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ROMA与RMI预测卵巢癌风险指数的比较研究 被引量：11

A Comparison of the Value of ROMA and RMI for Diagnosing Ovarian Cancer
下载PDF
导出
摘要 目的评价卵巢恶性肿瘤风险模型(ROMA)与恶性风险指数(RMI)预测卵巢癌风险率的价值并比较。方法收集182例良性卵巢肿瘤和110例卵巢癌患者,完善盆腔超声,CT和/MRI,酶联免疫(ELISA)法检测血清人附睾上皮分泌蛋白4(HE4)和CA125水平,根据公式计算RMI值和ROMA指数并进行比较。结果与良性卵巢肿瘤患者相比,卵巢癌患者血清HE4、CA125水平均增高,RMI值和ROMA指数亦增高,差异有统计学意义(P<0.05);ROMA指数的敏感性、特异性,阳性预测值(PPV)、阴性预测值(NPV)均高于RMI指数,差异有统计学意义(P<0.05)。结论对于术前筛查卵巢肿瘤性质,ROMA具有更高的可信度及临床应用前景。 Objective To consider the value of the risk ovarian malignancy algorithm（ROMA） and risk malignant indices（RMI）,and evaluate their utilit.Methods Patients with benign and malignant were included,and the results of ultrasound,CT and/or MRI were collected for calculating ROMA and RMI.The ROMA and RMI values were determined sensitivity and specificity of each parameter were calculated using receiver operating characteristic curves according to the area under the curve（AUC）.Results The serum levels of HE4 and CA125 in malignant ovarian were significantly higher than those in benign ovarian,so do the RMI and ROMA（P＆lt;0.05）.The sensitivities,specificity,positive and negative predictive value of ROMA are significantly higher than those of RMI（P＆lt;0.05）.Conclusion For preoperative screening for ovarian tumor,ROMA has a higher credibility and prospects for clinical application.
作者 陈亮香 王冬莲 李雪英 廖湘玲
机构地区 湖南省妇幼保健院妇科
出处 《湖南中医药大学学报》 CAS 2013年第6期53-54,65,共3页 Journal of Hunan University of Chinese Medicine
关键词 卵巢癌 卵巢恶性肿瘤风险模型 恶性风险指数 人附睾上皮分泌蛋白4 Ovarian Cancer Risk ovarian malignancy algorithm Risk malignant indices human epididymis protein 4
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Cancer Facts & Figures.American Cancer Society[M].2009:1-68.
  • 2Serov SF, Scully RE,Sobin LH.Histological Typing of Ovarian Tumors[J].WHO International Histological Classification of Tumors No.9.World Health Organization: Geneva,Switzerla nd, 1973,90(9):756-759.
  • 3Shepherd JH.Revised FIGO staging for gynaecological cancer[J].Br J Obstet Gynaeeol,1988,96(8): 889-892.
  • 4张超,崔恒,钱和年.卵巢癌化疗药物的新进展[J].中国妇产科临床杂志,2001,2(4):245-248. 被引量：2
  • 5Terry K, Sluss P, Skates S, et al. Blood and urine markers for ovarian cancer: a comprehensive review[J]. Dis Markers,2004,20(9):53-70.
  • 6Markman M. The role of CA-125 in the management of ovarian cancer[J]. Oncologist, 1997,21 (2):6-9.
  • 7Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature[J]. Hum Reprod,1989, 4(1):1-12.
  • 8Cristina A,Fliomena MC, Elci IO, et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm(ROMA), and risk malignancy index(RMI) for the classification of ovarian masses[J]. Clincs, 2012,67(5):437-441.
  • 9Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J]. Am J Obstet Gynecol,2010,203(3):228.
  • 10Holcomb K, Vucetic Z, Miller MC, et al. HE4 Offers Superior Specificity in the Differentiation of Benign and Malignant Adnexal Masses in Premenopausal Women[J]. Am J Obstet Gynecol, 2011, 205(4):358.

二级参考文献49

  • 1[1]Van Moorsel CJ, Pinedo HM, Veerman , et al. Mechanisms of synergism between cisplatin and gemcitabin on ovarian and non - small - cell lung cancer cell lines. Br J Cancer, 1999 , 80:981-990
  • 2[2]Hansen SW, Tuxen MK, Sessa S, et al. C emcitabine in the treatment of ovarian cancer. Ann Oncol, 1999, 10 (suppl 1) : 51-53
  • 3[3]McDonald AC, Brown R, et al. Induction of P53 - dependent and P53 independent cellular responses by topoisomerase I inhibitors. Br J Cancer,1998 , 78:745-751
  • 4[4]Bookman MA. Extending the platinum- free interval in recurrent ovarian cancer: the role of topotecan in second - line chemotherapy. Oncologia,1999, 4:87-94
  • 5[5]Bolise G, Scarfone G, Tateo S, et al. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first line treatment with carboplatinum and paclitaxel. Gynecol Oncol, 2001,80: 13- 15
  • 6[6]Frasci G, Panza P, Comella P, et al. Cisplatin - topotecan - paclitaxel weekly administration with G- CSF support for ovarian and small - cell lung cancer patients: a dose - finding study. Ann Oncol, 1999 , 10:355 - 358
  • 7[7]De Jong RS, Mulder NH, Vges DR, et al. Pandomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer, 1997, 75: 1660 - 1666
  • 8[8]Saphner T, Weller EA , Tormey DC, et al. 21 - Day oral etoposide for metastatic breast cancer. Am J Clin Oncol, 2000, 23:258-262
  • 9[9]Alberts DS. Treatment of refractory and recurrent ovarian cancer. Semin Oncol, 1999, 26 ( suppl ): 8-14
  • 10[10]Villena Heinsen C, Friedrich M, Etan AK, et al. Human tumour xenografsts in nude mice: chemotherapy trials with titanocene dichloride in different dosages. Glin Exp Obstet Gyneeol, 1998, 25:5-8

共引文献132

同被引文献97

  • 1刘伟,李苏宜.卵巢癌化疗新进展[J].肿瘤基础与临床,2006,19(6):526-528. 被引量：19
  • 2张雪玉.绝经后卵巢可及综合征[J].宁夏医学院学报,2007,29(1):105-106. 被引量：7
  • 3Moore RG,Mcmeekin DS,Brown AK,et al. A novel multiple marker bi- oassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol 0ncol,2009,112( 1 ) :40 -46.
  • 4Rosen DG,Wang L,Atkinson JN,et al. Potential markers that comple- ment expression of CA125 in epithelial ovarian cancer [ J ]. Gynecol 0nco1,2005,99 (2) :267 - 277.
  • 5Galgano MT, Hampton GM, Frierson HF, et al. Comprehensive analysis of HFA expression in normal and malignant human tissues [ J ]. Mod Patho1,2006,19 ( 9 ) : 847 - 853.
  • 6Hellstron I, Raycm J, Hayden - Ledbetter M, et al. The HFA ( WFDC2 ) protein is a biomarker for nvallan Carainoa [ J ]. Cancer Res, 2003,63 ( 13 ) :3695 - 3700.
  • 7Montagnana M, Lippi G Ruzzenente O, et al. The utility of serum hu- man epididymis protein4 ( HE4 )in patients with apelvicmass [ J ]. J Clin Lab Anal,2009,23 ( 5 ) :331 - 335.
  • 8Moore RG, Mc Meekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass [ J ]. Gynecologic Oncology, 2009,112 (1) :40 -46.
  • 9Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ]. Controlled Clinical Trials, 1996,17 ( 1 ) : 1 - 12.
  • 10Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy Index for the predic- tion of epithelial ovarian cancer in patients with a pelvic mass[J]. Am Jobstet Gyneco1,2010,203 ( 3 ) :228. e1 - e6.

引证文献11

二级引证文献118

湖南中医药大学学报
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部